Healthcare
China medical device player Hanyu Medical secures $72m
China-based medical devices manufacturer Hanyu Medical has raised a RMB500 million ($72 million) Series D co-led by HighLight Capital, CPE (formerly known as CITIC Private Equity), and Yingke Private Equity.
Japan's ACA exits aged care business
Tokyo-listed healthcare provider Solasto will acquire 100% of Japan Elderly Care Service for JPY2.3 billion ($22 million), providing an exit for local private equity firm ACA Investments.
China’s VC-backed CanSino raises $748m in Star Market IPO
Chinese vaccine developer CanSino Biologics, which counts Lily Asia Ventures (LAV) and Qiming Venture Partners among its investors, has raised RMB5.2 billion ($748 million) in an IPO on Shanghai’s Star Market.
China's Vision Medicals raises $28m
CDH Investment has led a RMB200 million ($28 million) Series B round for Guangzhou-based precision diagnosis and gene sequencing company Vision Medicals.
Yunfeng backs take-private of China-US biotech player
Yunfeng Capital, a private equity firm co-founded by Jack Ma, is backing the privatization of Cellular Biomedicine, a US and China-based biotech developer.
ByteDance acquires Chinese medical platform for $72m
ByteDance, the PE-backed owner of TikTok and the Toutiao news aggregation service, has acquired VC-backed Chinese medical information platform Baikemy for RMB500 million ($72 million).
Chinese CRO player Yaoyanshe raises $86m
Yaoyanshe, a Chinese contract research organization (CRO) for novel drugs, has raised RMB600 million ($86 million) across two rounds in the past eight months.
Huagai leads $43m round for China antibiotics developer
China-focused private equity firm Huagai Capital has a led a RMB300 million ($43 million) Series D round for antibiotics developer MicuRX Pharmaceuticals.
China's Sherpa closes debut US dollar fund at $200m
Sherpa Healthcare Partners, founded by former healthcare heads at Legend Capital, has closed its first US dollar fund at $200 million.
Legend leads $20m Series B for China's Exegenesis Bio
Chinese gene therapy specialist Exegenesis Bio has received $20 million in Series B funding led by Legend Capital. It will be used to support clinical development of the company’s drug portfolio.
Bain sweetens offer for Japan's Nichii Gakkan
Bain Capital has increased its offer price for Tokyo-listed aged care provider Nichii Gakkan – after a Hong Kong hedge fund criticized the board for not doing enough to protect the interests of minority shareholders – valuing the business at JPY122...
Tata Growth commits $30m to India's Biocon
Tata Capital Growth Fund has invested INR2.25 billion ($30 million) in the biosimilars business of India-listed pharmaceuticals giant Biocon.
Advent to acquire Indian pharma player
Advent International has agreed to buy a controlling stake in Indian pharmaceutical company RA Chem Pharma.
Deal focus: Haihe's biotech out-licensing ambition
Warburg Pincus picked Haihe Pharmaceutical as its first bet on innovative drug development in China, having been convinced by the company's mature portfolio and international expansion plans
Eurazeo commits $94m in debut Europe-China fund deal
French GP Eurazeo has made its debut investment from a newly launched Europe-China cross-border fund, committing EUR80 million ($94 million) to Dutch medical supplier DORC.
Healthcare investors warn Asia unprepared for winter - AVCJ Forum
Private equity professionals focusing on healthcare told the AVCJ Southeast Asia Virtual Forum that COVID-19’s full impact has yet to be understood. The private and public sectors will need to work together to see out a difficult year.
Warburg Pincus leads Series B for China's Haihe Pharmaceutical
Warburg Pincus has led a RMB1.2 billion ($171 million) Series B round for Haihe Pharmaceutical, a Chinese cancer drug developer that currently has four treatments in stage-three clinical trials or beyond.
Trustbridge spin-out Vitalbridge closes debut China fund
Vitalbridge Capital, a Chinese venture capital firm established by Jinjian Zhang, formerly of Trustbridge Partners, has raised $150 million for its debut fund.
Q&A: Novo Holdings' Amit Kakar
Having spent the past three years on healthcare buy-and-build platform Everlife Asia, Amit Kakar’s is joining life sciences investor Novo Holdings as regional head. He explains why now is the time to bet big on Asia
China biotech player Antengene raises $97m Series C
Fidelity Investments has led a $97 million Series C round for Chinese hematology and oncology biotech developer Antengene.
DCP, Qiming support China medical devices fund
Ascendum Capital Partners, a healthcare investment firm established by DCP Capital, Qiming Venture Partners and Chinese medical devices manufacturer Venus Medtech, is looking to raise $200 million for its debut fund.
PE-backed Junshi Biosciences shines on Star Market debut
PE-backed Junshi Biosciences has become the first Chinese biotech company to list in Hong Kong and the mainland, following a strong debut on Shanghai's Star Market.
Chinese biotech company Arctic Vision raises $32m
China-based ophthalmology therapy provider Arctic Vision has raised a $32 million Series A round led by Morningside Ventures.
China cancer test kit provider gets $30m Series E
New Horizon Health, a China-based manufacturer of cancer testing kits for use at home, has raised $30 million in a Series E round of funding led by Rock Springs Capital.